Efficacy of first-line ART regimens based on tenofovir in HIV-infected patients with pre-existing A62V mutation in reverse transcriptase
- 作者: Ozhmegova E.N.1, Kuznetsova A.I.1, Lebedev A.V.1, Antonova A.A.1, Kim K.V.1, Munchak Y.M.1, Tumanov A.S.1, Kazennova E.V.1
-
隶属关系:
- National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health
- 期: 卷 69, 编号 3 (2024)
- 页面: 231-240
- 栏目: ORIGINAL RESEARCH
- URL: https://ogarev-online.ru/0507-4088/article/view/259215
- DOI: https://doi.org/10.36233/0507-4088-232
- EDN: https://elibrary.ru/lnmvih
- ID: 259215
如何引用文章
详细
Introduction. The amino acid substitution A62V in reverse transcriptase was identified as a mutation correlated with virologic failure in patients on first-line therapy including tenofovir (TDF) and tenofovir alafenamide (TAF). A62V is a typically polymorphic mutation in HIV-1 sub-subtype A6, which is the most widespread virus variant in Russia.
Materials and methods. The European EuResist (EIDB) database was queried to form two equivalent groups of patients: group 1 ‒ patients with A62V at baseline treated with TDF or TAF on the first-line therapy, group 2 ‒ patients without A62V at baseline treated with TDF or TAF on the first-line therapy. Each group included 23 patients.
Results. There was no statistical difference between the two groups in virologic efficacy in 4, 12, and 24 weeks after the start of antiretroviral therapy (ART) and in the frequency of virologic failures.
Conclusion. This study has some limitations, and the exact role of A62V in the efficacy of the first-line ART based on tenofovir deserves further investigation.
作者简介
Ekaterina Ozhmegova
National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health
编辑信件的主要联系方式.
Email: ozhmegova.eka@gmail.com
ORCID iD: 0000-0002-3110-0843
PhD, Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky
俄罗斯联邦, MoscowAnna Kuznetsova
National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health
Email: a-myznikova@list.ru
PhD, Head of the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky
俄罗斯联邦, MoscowAleksey Lebedev
National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health
Email: lebedevalesha236@gmail.com
ORCID iD: 0000-0001-6787-9345
PhD, Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky
俄罗斯联邦, MoscowAnastasia Antonova
National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health
Email: anastaseika95@mail.ru
ORCID iD: 0000-0002-9180-9846
PhD, Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky
俄罗斯联邦, MoscowKristina Kim
National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health
Email: kimsya99@gmail.com
ORCID iD: 0000-0002-4150-2280
Junior Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky
俄罗斯联邦, MoscowYana Munchak
National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health
Email: yanka.zabavnaya@mail.ru
ORCID iD: 0000-0002-4792-8928
Junior Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky
俄罗斯联邦, MoscowAlexander Tumanov
National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health
Email: desep@mail.ru
ORCID iD: 0000-0002-6221-5678
Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky
俄罗斯联邦, MoscowElena Kazennova
National Research Center for Epidemiology and Microbiology named after the Honorary Academician N.F. Gamaleya of the Russian Ministry of Health
Email: kazennova@rambler.ru
ORCID iD: 0000-0002-7912-4270
D. Sc. (Biology), Leading Researcher at the Laboratory of Leukemia Viruses of the Department of the Institute of Virology named after. D.I. Ivanovsky
俄罗斯联邦, Moscow参考
- Stanford University HIV Drug Resistance Database. Available at: http://hivdb.stanford.edu
- Wensing A.M., Calvez V., Ceccherini-Silberstein F., Charpentier C., Günthard H.F., Paredes R., et al. 2022 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 2022; 30(4): 559–74.
- Maldonado J.O., Mansky L.M. The HIV-1 reverse transcriptase A62V mutation influences replication fidelity and viral fitness in the context of multi-drug-resistant mutations. Viruses. 2018; 10(7): 376. DOI: https://doi.org/10.3390/v10070376
- Svarovskaia E.S., Feng J.Y., Margot N.A., Myrick F., Goodman D., Ly J.K., et al. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 2008; 48(4): 428–36. DOI: https://doi.org/10.1097/QAI.0b013e31817bbe93
- Rhee S.Y., Varghese V., Holmes S.P., Van Zyl G.U., Steegen K., Boyd M.A., et al. Mutational correlates of virological failure in individuals receiving a WHO-recommended Tenofovir-containing first-line regimen: an international collaboration. EBioMedicine. 2017; 18: 225–35. DOI: https://doi.org/10.1016/j.ebiom.2017.03.024
- Wagner T., Zuckerman N.S., Halperin T., Chemtob D., Levy I., Elbirt D., et al. Epidemiology and transmitted HIV-1 drug resistance among treatment-naive individuals in Israel, 2010–2018. Viruses. 2021; 14(1): 71. DOI: https://doi.org/10.3390/v14010071
- Zhukova A., Dunn D., Gascuel O. Modeling drug resistance emergence and transmission in HIV-1 in the UK. Viruses. 2023; 15(6): 1244. DOI: https://doi.org/10.3390/v15061244
- Kazennova E.V., Lapovok I.A., Laga V.Y., Vasilyev A.V., Bobkova M.R. Natural polymorphisms of HIV-1 IDU-A variant pol gene. VICh-infektsiya i immunosupressii. 2012; 4(4): 44–51. EDN: https://elibrary.ru/pjowuj (in Russian)
- Kirichenko A.A., Kireev D.E., Shlykova A.V., Lopatukhin A.E., Lapovok I.A., Saleeva D.V., et al. HIV-1 drug resistance in patients with virological inefficiency on ART in Russia in 2013–2021. Epidemiologiya i infektsionnye bolezni. Aktual’nye voprosy. 2021; 11(3): 53–62. DOI: https://doi.org/10.18565/epidem.2021.11.3.53-62 EDN: https://elibrary.ru/uqiuni (in Russian)
- Ministry of Health of the Russian Federation. Clinical Guidelines «HIV Infection in Adults»; 2020. Available at: http://rushiv.ru/wp-content/uploads/2022/11/KR79.pdf (in Russian)
- Clinicalinfo. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-arv/guidelines-adult-adolescent-arv.pdf
- Bbosa N., Kaleebu P., Ssemwanga D. HIV subtype diversity worldwide. Curr. Opin. HIV AIDS. 2019; 14(3): 153–60. DOI: https://doi.org/10.1097/coh.0000000000000534
- Kirichenko A., Lapovok I., Baryshev P., van de Vijver D., van Kampen J.J.A., Boucher C.A.B., et al. Genetic features of HIV-1 integrase sub-subtype A6 predominant in Russia and predicted susceptibility to INSTIs. Viruses. 2020; 12(8): 838. DOI: https://doi.org/10.3390/v12080838
- Kuznetsova A., Lebedev A., Gromov K., Kazennova E., Zazzi M., Incardona F., et al. Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line ART regimens using rilpivirine in human immunodeficiency virus-infected patients. Clin. Case Rep. 2022; 10(2): e05373. DOI: https://doi.org/10.1002/ccr3.5373
- Sukhanova A.L., Rudinskii N.I., Bogoslovskaya E.V., Kruglova A.I., Bashkirova L.Yu., Tsyganova G.M., et al. Polymorphism of the genome region coding for protease and reverse transcriptase in HIV type 1 subtype a variants prevailing in CIS countries. Molekulyarnaya biologiya. 2005; 39(6): 934–41. DOI: https://doi.org/10.1007/s11008-005-0115-8 EDN: https://elibrary.ru/ljarmp
- Kolomeets A.N., Varghese V., Lemey P., Bobkova M.R., Shafer R.W. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. Aids. 2014; 28(17): F1–8. DOI: https://doi.org/10.1097/qad.0000000000000485
- Kirichenko A., Kireev D., Lopatukhin A., Murzakova A., Lapovok I., Saleeva D., et al. Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries. PLoS One. 2022; 17(1): e0257731. DOI: https://doi.org/10.1371/journal.pone.0257731
- Shchemelev A.N., Ostankova Yu.V., Valutite D.E., Serikova E.N., Zueva E.B., Semenov A.V., et al. Risk assessment of first-line treatment failure in untreated HIV patients in Northwestern federal district of the Russian Federation. Infektsiya i immunitet. 2023; 13(2): 302–8. DOI: https://doi.org/10.15789/2220-7619-RAO-2122 EDN: https://elibrary.ru/ciclmu (in Russian)
- Costa B., Vale N. Efavirenz: history, development and future. Biomolecules. 2022; 13(1): 88. DOI: https://doi.org/10.3390/biom13010088
- Lv Z., Chu Y., Wang Y. HIV protease inhibitors: a review of molecular selectivity and toxicity. HIV AIDS (Auckl.). 2015; 7: 95–104. DOI: https://doi.org/10.2147/hiv.S79956
- Salvaña E.M.T., Dungca N.T., Arevalo G., Li K., Francisco C., Penalosa C., et al. HIV-1 subtype shift in the Philippines is associated with high transmitted drug resistance, high viral loads, and fast immunologic decline. Int. J. Infect. Dis. 2022; 122: 936–43. DOI: https://doi.org/10.1016/j.ijid.2022.06.048
补充文件
